Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Abstract Background The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell transplant, we investigated the in vitro activity of daratumumab on mo...

Full description

Bibliographic Details
Main Authors: Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga, Raymond L. Comenzo
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Experimental Hematology & Oncology
Subjects:
Myeloma
Daratumumab
CD34+
Progenitor cells
Online Access:http://link.springer.com/article/10.1186/s40164-018-0119-4

Internet

http://link.springer.com/article/10.1186/s40164-018-0119-4

Similar Items